



Northern Lincolnshire
Area Prescribing Committee

>>>>>> August 2014

New Patient Treatments

Several new treatments have been supported for use in Northern Lincolnshire.

These are:

Anoro Ellipta in Chapter 3.1.4. This is a long acting beta agonist (LABA) combined with a long acting muscarinic antagonist (LAMA) that is used in the treatment of COPD. Anoro Ellipta contains vilanterol and umeclidinium. The APC COPD Pathway will be updated in due course once local clinicians have more experience with the novel Ellipta devices. The cost of Anoro Ellipta is currently £32.50, which makes this a cost effective treatment when a LAMA alone is not providing ideal outcomes. A single LAMA such as glycopyrronium bromide (Seebri) will remain first choice. Please note that for 30 days treatment, LAMA devices including Spiriva refill capsules, Eklira Genuair and Seebri cost £33.50, £28.60 and £27.50 respectively.

Ganfort UDVs and Monopost UDVs in Chapter 11.6. These are only to be used in patients who have sensitivities to the preservatives used in ordinary eye drops. Ganfort contains bimatoprost and timolol. Monopost contains latanoprost. Both these are used to treat raised intra-ocular pressure in open-angle glaucoma. Ganfort and Monopost are both brand names. If in future several brands with the same ingredients and indications exist, we would recommend prescribing generically to maintain optimal selection.

Icatibant in Chapter 3.4.3. This is a rarely used yet essential treatment for acute attacks of hereditary angioedema in patients with C1-esterase inhibitor deficiency. This will only be initiated by hospital specialists and made available through primary care if needed. The brand name is Firazyr. This is a sub-cutaneous injection available in 3ml pre-filled syringes.

Canagliflozin in Chapter 6.1.2.3. This is an SGLT2, similar to dapagliflozin. There are two strengths of canagliflozin tablets (100mg and 300mg). Canagliflozin is to be used as per NICE TA315.

MHRA Safety Updates

The APC are intending to produce an annual summary of the safety updates that commonly affect day to day practice in primary care. This will be published on the APC website.